(Total Views: 173)
Posted On: 06/19/2017 10:16:28 PM
Post# of 23071
$RIGL,,This was announced today:
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) announced the FDA has accepted its New Drug Application (NDA) for the use of TAVALISSE (fostamatinib disodium) in patients with chronic or persistent immune thrombocytopenia (ITP). The PDUFA date is April 17, 2018. Shares rallied to close up 11% to $2.78 as the filing was a welcome relief for the company and investors as in its Phase 3 trials only one of the two trials met the primary endpoints.
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) announced the FDA has accepted its New Drug Application (NDA) for the use of TAVALISSE (fostamatinib disodium) in patients with chronic or persistent immune thrombocytopenia (ITP). The PDUFA date is April 17, 2018. Shares rallied to close up 11% to $2.78 as the filing was a welcome relief for the company and investors as in its Phase 3 trials only one of the two trials met the primary endpoints.
(1)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
